BioNTech SE (NASDAQ:BNTX – Get Free Report)’s stock price hit a new 52-week high during trading on Tuesday after UBS Group raised their price target on the stock from $97.00 to $131.00. UBS Group currently has a neutral rating on the stock. BioNTech traded as high as $131.49 and last traded at $130.46, with a volume of 696530 shares trading hands. The stock had previously closed at $123.47.
Several other research firms also recently commented on BNTX. HC Wainwright reaffirmed a “buy” rating and set a $113.00 price objective on shares of BioNTech in a research note on Monday. Deutsche Bank Aktiengesellschaft upgraded BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price target for the company in a research note on Wednesday, August 7th. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. raised shares of BioNTech from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $91.00 to $125.00 in a research note on Monday. Finally, TD Cowen reduced their target price on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $120.31.
View Our Latest Research Report on BNTX
Institutional Investors Weigh In On BioNTech
BioNTech Trading Down 7.3 %
The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The stock has a market cap of $27.49 billion, a PE ratio of 231.24 and a beta of 0.23. The business has a 50-day moving average of $89.02 and a 200 day moving average of $90.14.
BioNTech (NASDAQ:BNTX – Get Free Report) last issued its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. During the same period last year, the business posted ($0.86) earnings per share. The company’s quarterly revenue was down 23.3% compared to the same quarter last year. Equities research analysts predict that BioNTech SE will post -2.8 EPS for the current fiscal year.
About BioNTech
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Read More
- Five stocks we like better than BioNTech
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- How Much Can You Make in Stocks in One Month?
- Manufacturing Stocks Investing
- This Is the Top Large-Cap Stock Insiders Are Buying
- How to Find Undervalued Stocks
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.